{"id":5352,"date":"2012-01-22T23:55:59","date_gmt":"2012-01-22T23:55:59","guid":{"rendered":"http:\/\/www.homeobook.com\/?p=5352"},"modified":"2022-01-11T10:08:37","modified_gmt":"2022-01-11T10:08:37","slug":"the-haunting-of-medical-journals-how-ghostwriting-sold-hrt","status":"publish","type":"post","link":"https:\/\/www.homeobook.com\/the-haunting-of-medical-journals-how-ghostwriting-sold-hrt\/","title":{"rendered":"The Haunting of Medical Journals: How Ghostwriting Sold \u201cHRT\u201d"},"content":{"rendered":"
Provide unprecedented insights into how pharmaceutical companies promote drugs, including the use of vendors to produce ghostwritten manuscripts and place them into medical journals<\/strong><\/span><\/p>\n Unregulated Marketing through Medical Journals Summary Points<\/strong><\/p>\n Medicine, as a profession, must take responsibility for this situation. Na\u00efvet\u00e9 is no longer an excuse. Perhaps physician-investigators should create and uphold a standard where relationships with industry are regarded as unsavory rather than sought after. Academic institutions and medical journals should take a hard line on ghostwriting. Patient care will benefit if physicians draw together as a profession to denormalize relationships with industry and avoid the role of corporate pawns in the future.\u00a0\u00a0<\/strong><\/p>\n It is illegal for pharmaceutical companies to promote a marketed drug for off-label use, i.e., for uses other than those approved by the U.S. Food and Drug Administration (FDA) or equivalent national agencies. Articles in medical journals, newsletters, and magazines, however, are not considered promotional. As an industry article states, \u201cPeer-reviewed publications offer pharma companies shelter from often-stormy regulatory waters. FDA views published articles as protected commercial speech so doesn’t regulate their content\u201d<\/p>\n In the absence of data (or in the presence of data adverse to marketing goals), review articles in medical journals are crucial vehicles for encouraging off-label uses, promoting unproven benefits, and for downplaying harms. Narrative reviews summarize and analyze prevailing literature and often offer clinical recommendations. Commentaries and other opinion pieces are also highly valued because they provide clinical direction, and are usually not peer-reviewed. Presentations at medical meetings are important for the same reason<\/p>\n As shows, DesignWrite helped to produce numerous ghostwritten reviews and commentaries, including articles designed to promote the off-label use of Prempro for preventing<\/strong> Alzheimer’s disease, Parkinson’s disease, age-related macular degeneration, and wrinkles. The scope of these articles is summarized . The DesignWrite documents avoid discussing off-label marketing, but noted that reviews can \u201cDisseminate messages that fill the gaps not addressed by current studies\u201d. Another document noted that the \u201cStrategic Publications Team\u201d should \u201cIdentify data gaps\u201d and \u201cFill the gap with review papers\u201d<\/p>\n Read full paper<\/strong> : http:\/\/www.plosmedicine.org\/article\/info:doi\/10.1371\/journal.pmed.1000335?ref=nf<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Provide unprecedented insights into how pharmaceutical companies promote drugs, including the use of vendors to produce ghostwritten manuscripts and place them into medical journals Unregulated Marketing through Medical Journals Adriane Fugh-Berman examines documents unsealed in […]<\/a><\/p>\n<\/div>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[1221,1222],"class_list":{"0":"post-5352","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-research-homoeopathy","7":"tag-the-haunting-of-medical-journals","8":"tag-unregulated-marketing-through-medical-journals"},"yoast_head":"\n
\n<\/strong>Adriane Fugh-Berman examines documents unsealed in recent litigation to investigate how pharmaceutical companies promoted hormone therapy drugs, including the use of medical writing companies to produce ghostwritten manuscripts and place them into medical journals.<\/p>\n\n